Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Free Radic Biol Med ; 104: 371-379, 2017 03.
Article in English | MEDLINE | ID: mdl-28179110

ABSTRACT

Certain mitochondrial components can act as damage-associated molecular patterns (DAMPs) or danger signals, triggering a proinflammatory response in target (usually immune) cells. We previously reported the selective degradation of mitochondrial DNA and RNA in response to cellular oxidative stress, and the immunogenic effect of this DNA in primary mouse astrocytes. Here, we extend these studies to assess the immunogenic role of both mitochondrial DNA and RNA isolated from hydrogen peroxide (HP) treated HA1 cells (designated "DeMPs" for degraded mitochondrial polynucleotides) using mouse bone marrow derived macrophages (BMDMs), a conventional immune cell type. DeMPs and control mitochondrial DNA (cont mtDNA) and RNA (cont mtRNA) were transfected into BMDMs and cell-free media analyzed for the presence of proinflammatory cytokines (IL-6, MCP-1, and TNFα) and Type I interferon (IFN-α and IFN-ß). Cont mtDNA induced IL-6 and MCP-1 production, and this effect was even greater with DeMP DNA. A similar response was observed for Type I interferons. An even stronger induction of proinflammatory cytokine and type 1 interferons was observed for cont mtRNA. However, contrary to DeMP DNA, DeMP RNA attenuated rather than potentiated the cont mtRNA cytokine inductions. This attenuation effect was not accompanied by an IL-10 or TGFß anti-inflammatory response. All DeMP effects were observed at multiple oxidant concentrations. Finally, DeMP production and immunogenicity overlaps with cellular adaptive response and so may contribute to cellular oxidant protection. These results provide new insight into the immunogenicity of mitochondrial polynucleotides, and identify new roles and selective consequences of cellular oxidation.


Subject(s)
Macrophages/metabolism , Mitochondria/drug effects , Oxidative Stress/drug effects , RNA/genetics , Animals , Cytokines/biosynthesis , DNA, Mitochondrial/drug effects , DNA, Mitochondrial/genetics , DNA, Mitochondrial/metabolism , Hydrogen Peroxide/toxicity , Macrophages/drug effects , Macrophages/pathology , Mice , Mitochondria/metabolism , Mitochondria/pathology , Mitophagy/drug effects , Mitophagy/genetics , Oxidation-Reduction , Oxidative Stress/genetics , RNA/metabolism , RNA Stability/drug effects , RNA Stability/genetics , RNA, Mitochondrial
2.
Nutr Res ; 35(5): 440-8, 2015 May.
Article in English | MEDLINE | ID: mdl-25799055

ABSTRACT

We have considered a novel gene targeting approach for treating pathologies and conditions whose genetic bases are defined using diet and nutrition. One such condition is Down syndrome, which is linked to overexpression of RCAN1 on human chromosome 21 for some phenotypes. We hypothesize that a decrease in RCAN1 expression with dietary supplements in individuals with Down syndrome represents a potential treatment. Toward this, we used in vivo studies and bioinformatic analysis to identify potential healthy dietary RCAN1 expression modulators. We observed Rcan1 isoform 1 (Rcan1-1) protein reduction in mice pup hippocampus after a 4-week curcumin and fish oil supplementation, with only fish oil reduction being statistically significant. Focusing on fish oil, we observed a 17% Rcan1-1 messenger RNA (mRNA) and 19% Rcan1-1 protein reduction in BALB/c mice after 5 weeks of fish oil supplementation. Fish oil supplementation starting at conception and in a different mouse strain (C57BL) led to a 27% reduction in hippocampal Rcan1-1 mRNA and a 34% reduction in spleen Rcan1-1 mRNA at 6 weeks of age. Hippocampal protein results revealed a modest 11% reduction in RCAN1-1, suggesting translational compensation. Bioinformatic mining of human fish oil studies also revealed reduced RCAN1 mRNA expression, consistent with the above studies. These results suggest the potential use of fish oil in treating Down syndrome and support our strategy of using select healthy dietary agents to treat genetically defined pathologies, an approach that we believe is simple, healthy, and cost-effective.


Subject(s)
Dietary Supplements , Down Syndrome/metabolism , Fish Oils/therapeutic use , Gene Expression Regulation, Developmental , Hippocampus/metabolism , Intracellular Signaling Peptides and Proteins/antagonists & inhibitors , Maternal Nutritional Physiological Phenomena , Muscle Proteins/antagonists & inhibitors , Animals , Animals, Newborn , Calcium-Binding Proteins , Down Syndrome/diet therapy , Down Syndrome/genetics , Down Syndrome/prevention & control , Down-Regulation , Female , Hippocampus/growth & development , Intracellular Signaling Peptides and Proteins/genetics , Intracellular Signaling Peptides and Proteins/metabolism , Mice, Inbred BALB C , Mice, Inbred C57BL , Muscle Proteins/genetics , Muscle Proteins/metabolism , Nerve Tissue Proteins/antagonists & inhibitors , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Neurons/metabolism , Pregnancy , Protein Isoforms/antagonists & inhibitors , Protein Isoforms/genetics , Protein Isoforms/metabolism , RNA, Messenger/metabolism , Species Specificity , Spleen/growth & development , Spleen/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...